ArticleFrontiers in oncology2026
Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chromosome 1q abnormalities are among the most frequent cytogenetic alterations in multiple myeloma (MM), yet their prognostic relevance has been reported inconsistently and varies across current risk stratification models. Methods: We conducted a retrospective single-center study to evaluate the clinical impact of 1q abnormalities in 140 patients with newly diagnosed MM undergoing autologous stem cell transplantation (ASCT). Results: Fluorescence Conclusion: In conclusion, the prognostic relevance of chromosome 1q alterations in transplant-eligible newly diagnosed MM appears to be primarily driven by copy number burden and co-occurrence with other high-risk lesions rather than by their isolated presence. These findings support the integration of 1q abnormalities into composite risk models to improve risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.